Analyst firms · UBS · VTRS
UBS VTRS price target and rating history
Viatris Inc. (VTRS) · Health Care
UBS rates Viatris Inc. (VTRS) Buy with a $18 price target, as of its latest action on Feb 9, 2026. It has published 3 rating actions on VTRS since June 2022, including 2 upgrades and 0 downgrades. Across 5 firms with a VTRS price target in the last 12 months, the median target is $18. UBS's target matches it.
- Current rating
- Buy
- Price target
- $18
- Median target, all firms
- $18
- Actions on VTRS
- 3
UBS price target on VTRS
Every UBS rating on VTRS
- Feb 9, 2026
- Nov 10, 2022
- Jun 14, 2022
How other firms rate VTRS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Oppenheimer | Outperform | $25 | Sep 23, 2026 |
| Leerink Partners | Outperform | $20 | Sep 9, 2026 |
| UBS | Buy | $18 | Feb 9, 2026 |
| Argus Research | Buy | $15 | Jan 16, 2026 |
| Barclays | Overweight | $15 | Dec 9, 2025 |
Questions about UBS and VTRS
- What is UBS's price target for VTRS?
- UBS's latest stated price target for Viatris Inc. (VTRS) is $18, from its action on Feb 9, 2026.
- What is UBS's rating on VTRS?
- UBS rates VTRS Buy, a bullish rating, as of Feb 9, 2026.
- When did UBS last change its view on VTRS?
- On Feb 9, 2026, UBS upgrades to Buy from Neutral, price target $18.
- How does UBS's VTRS target compare with other analysts?
- Across 5 firms with a VTRS price target in the last 12 months, the median target is $18. UBS's target matches it.
More VTRS rating histories
All UBS ratingsVTRS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.